Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syngen Biotech CoROCO:8279 +1.03%89 Operating Margin % is 8.34% as of Dec. 2025, which is 51% below its 10-year median of 17.04. GuruFocus rates ROCO:8279 with a GF Score™ of 89/100 and a GF Value™ of NT$158.16 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 940 Biotechnology companies, Syngen Biotech Co ranks better than 84.68% on this metric.
Syngen Biotech Co (ROCO:8279) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Syngen Biotech Co Operating Margin % Related Terms
Syngen Biotech Co Operating Margin % Historical Data
* Premium members only.
The historical data trend for Syngen Biotech Co's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8279 vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Syngen Biotech Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syngen Biotech Co Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syngen Biotech Co's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Syngen Biotech Co's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Syngen Biotech Co's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syngen Biotech Co (ROCO:8279) has a Operating Margin % of 8.34% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Syngen Biotech Co and its competitors. This is 51% below median its historical median of 17.04. Over the past decade, Syngen Biotech Co's Operating Margin % has ranged from 15.05 to 19.69. According to the industry distribution chart, Syngen Biotech Co ranks #144 out of 940 companies in the Biotechnology industry, placing it in the top 15.3%.
Is Syngen Biotech Co's Operating Margin % too high?
Syngen Biotech Co's current Operating Margin % of 8.34% is 51% below median its 10-year median of 17.04. Over the past 10 years, this metric has ranged from a low of 15.05 to a high of 19.69. Based on the distribution chart, Syngen Biotech Co ranks #144 out of 940 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Syngen Biotech Co has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngen Biotech Co's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Syngen Biotech Co ranks #144 out of 940 companies for Operating Margin %. This places Syngen Biotech Co in the top 15% of its industry — outperforming the majority of peers. Historically, Syngen Biotech Co's own Operating Margin % has ranged from 15.05 to 19.69 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Syngen Biotech Co and its competitors. Syngen Biotech Co's current Operating Margin % is 8.34%, which is 51% below median its own 10-year median of 17.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Syngen Biotech Co (ROCO:8279) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$158.16, compared to a current price of NT$88.50 — trading 44% below its estimated fair value. The current Operating Margin % is 8.34%, which is 51% below median its 10-year median of 17.04. Syngen Biotech Co's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Syngen Biotech Co (ROCO:8279), the current Operating Margin % is 8.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syngen Biotech Co (ROCO:8279) Overvalued in 2026?
Based on GuruFocus' analysis, Syngen Biotech Co stock appears to be undervalued.
The current stock price of NT$88.50 is trading 44% below its estimated GF Value™ of NT$158.16.
GuruFocus considers Syngen Biotech Co to be Significantly Undervalued.
Key valuation signals for ROCO:8279:
Operating Margin %: 8.34% (51% below median its 10-year median of 17.04)
GF Value™: NT$158.16 vs. price of NT$88.50 (44% below fair value)
No single metric tells the full story. See the ROCO:8279 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syngen Biotech Co Ltd is a biotechnology company. It is engaged in the manufacturing, sales, and trading of microbial pharmaceutical raw materials. It also provides the design and development of health food and biochemical nutrition. The company's products include pharmaceutical ingredients, nutritional ingredients, biology fermentation products, biology agriculture and aquaculture products.
89GF Score
Get the complete analysis for ROCO:8279
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8279 has been successfully added to your 
